Pipeline
Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to help transform the lives of patients with cancer.
Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to help transform the lives of patients with cancer.
Our programs are grounded in rational science to identify and treat patients most likely to respond to Mirati’s targeted therapies. Click on each program to learn more.
Adagrasib (MRTX849) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. This attribute could be important to treat KRASG12C mutated cancers, as the KRASG12C protein regenerates every 24 to 48 hours.
Approach
Optimization
MRTX1133 is an investigational, highly selective and potent small molecule inhibitor of the KRASG12D mutation.
Approach
Optimization
Sitravatinib is an investigational spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can potentially stimulate the body’s immune response to fight cancer.
Approach
Optimization
MRTX1719 is an investigational, internally discovered synthetic lethal MTA Cooperative PRMT5 inhibitor for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers.
Approach
Optimization
MRTX0902 is an investigational, selective SOS1 inhibitor that disrupts the SOS1:KRAS Interaction.
Approach
Optimization
Approach
Optimization
POC = proof of concept; P = Phase; L= Line; NSCLC = non-small cell lung cancer; CRC = colorectal cancer; OS = overall survival; IND = investigational new drug; NDA = new drug application; TPS = tumor proportion score; BID = twice daily dosing; ORR = objective response rate; MTAP = methylthioadenosine phosphorylase; CNS = central nervous system; S = squamous; NS = non-squamous.
1. BeiGene is currently conducting certain combination studies of sitravatinib + tislelizumab for solid tumor indications in their territory in Asia (ex-Japan). These trials include a P3 trial in non-squamous and squamous NSCLC randomized vs. docetaxel, as well as proof-of-concept trials in hepatocellular carcinoma, renal cell carcinoma, ovarian cancer and gastric.